Organon acquires Dermavant Sciences Ltd

Organon to Acquire Dermavant Sciences Ltd. with Focus on Innovative Dermatologic Therapy VTAMA® (tapinarof) Cream, 1%

09/18/24, 11:32 AM

Industry

therapeutics

biotechnology

health care

Organon, a global healthcare company focused on improving women's health, has announced the acquisition of Dermavant Sciences Ltd. This strategic move is aimed at expanding Organon's healthcare solutions by adding Dermavant's innovative dermatologic therapy VTAMA® (tapinarof) Cream, 1% for the treatment of psoriasis and atopic dermatitis.

Company Info

Company

Organon

Company info

Organon is a global healthcare company formed through a spin-off from Merck, (NYSE: MRK) known as MSD outside of the United States and Canada, to focus on improving the health of women throughout their lives. Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the women’s health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in innovation and future growth opportunities in women’s health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets. Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,500 employees with headquarters located in Jersey City, New Jersey. For more information, visit http://www.organon.com and connect with us on LinkedIn and Instagram.

Company news

Thu, 01 May 2025 07:00:00 GMT

Organon Reports Results for the First Quarter Ended March 31, 2025 - Business Wire

Tue, 15 Apr 2025 07:00:00 GMT

Organon Earnings Alert: Q1 2025 Results Coming May 1 with $6M Milestone Expenses - Stock Titan

Tue, 17 Sep 2024 07:00:00 GMT

Organon Issues 2023 ESG Report, Highlighting Strides in Women’s Health Equity and Environmental Stewardship - 3BL Media

Tue, 04 Jun 2024 07:00:00 GMT

Organon (OGN): Company Profile, Stock Price, News, Rankings - Fortune

Sun, 13 Apr 2025 01:25:00 GMT

European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11 - 뉴스와이어

Tue, 15 Apr 2025 07:00:00 GMT

Organon Appoints Ramona A. Sequeira to the Company’s Board of Directors - Business Wire

Fri, 24 May 2024 07:00:00 GMT

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia - Business Wire

Tue, 20 Aug 2024 07:00:00 GMT

Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets - Business Wire

Mon, 31 Mar 2025 07:00:00 GMT

(tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA - Business Wire

Thu, 31 Oct 2024 07:00:00 GMT

Organon Reports Results for the Third Quarter Ended September 30, 2024 - Business Wire

Unlock Strategic Intelligence with Fundz

This is just a small preview. Unlock the full dataset of company insights, strategic events, and leadership shifts — all in one platform.

Trusted by sales, BD, and investment teams at Oracle, HubSpot, Affinity, and more.

Related people

Trends

	Raised	Growth The data in the raised column shows reported funding for this location/industry over last 90 days. The data in the growth column indicates the % increase or decrease of the last 90 days vs. the previous 90 days. Please note: one or more large fundings, especially for a location/industry that doesn't historically receive much funding, can have a significant impact on the increase or decrease percentage.
biotechnology	$9.4 B	-17.2%
health care	$8 B	-30.5%
therapeutics	$1.7 B	-38.3%